Literature DB >> 9152603

Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily.

A D Rodrigues1, E M Roberts, D J Mulford, Y Yao, D Ouellet.   

Abstract

In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) protein(s) involved in the oxidative metabolism of [14C]clarithromycin (CLAR) in the presence of native human liver microsomes. The identity of the two major CLAR metabolites present in microsome incubates, 14-(R)-hydroxy-CLAR and N-desmethyl-CLAR, was confirmed by MS. Over the CLAR concentration range of 1.0-140 microM, the rate of CLAR 14-(R)-hydroxylation (KM = 48 +/- 17.7 microM; Vmax = 206 +/- 76 pmol/min/mg protein; Vmax/KM = 4.2 +/- 0.21 microliters/min/mg; mean +/- SD, N = 3 livers) and N-demethylation (KM = 59.1 +/- 24.0 microM; Vmax = 189 +/- 52.0 pmol/min/mg protein; Vmax/KM = 3.3 +/- 0.53 microliters/min/mg) conformed to monophasic (saturable) Michaelis-Menten kinetics and was highly correlated (r = 0.90-0.92; p < 0.001; N = 11) with CYP3A-selective erythromycin N-demethylase activity. Ketoconazole (< or = 2.0 microM) or troleadomycin, CYP3A-selective inhibitors, markedly decreased (> or = 99%) the formation of both metabolites, whereas inhibitors selective of other CYP forms were relatively ineffective (< or = 10% inhibition). In agreement with chemical inhibitor studies, CLAR metabolism was only detectable with human B-lymphoblastoid microsomes containing cDNA-expressed CYP3A4 (vs. CYP2C19, CYP2C9, CYP2D6, CYP1A2, CYP2E1, or CYP2A6). Furthermore, the apparent KM characterizing the 14-(R)-hydroxylation and N-demethylation of CLAR in the presence of insect cell microsomes containing cDNA-expressed CYP3A4 (KM = 18-63 microM) was similar to that obtained with native human liver microsomes. Based on the results of this study, it is concluded that the 14-(R)-hydroxylation and N-demethylation of CLAR is primarily mediated by one or more members of the human liver CYP3A subfamily.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9152603

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  28 in total

1.  Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration.

Authors:  Julius O Soyinka; Cyprian O Onyeji; Sharon I Omoruyi; Adegbenga R Owolabi; Pullela V Sarma; James M Cook
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

2.  To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics.

Authors:  Sieto Bosgra; Maria L H Vlaming; Wouter H J Vaes
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

3.  Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers.

Authors:  R Michael Baldwin; Staffan Ohlsson; Rasmus Steen Pedersen; Jessica Mwinyi; Magnus Ingelman-Sundberg; Erik Eliasson; Leif Bertilsson
Journal:  Br J Clin Pharmacol       Date:  2008-02-20       Impact factor: 4.335

4.  Twice-daily standard dose of omeprazole achieves the necessary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy.

Authors:  G Manes; O Pieramico; F Perri; D Vaira; N Giardullo; M Romano; G Nardone; A Balzano
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

5.  Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin.

Authors:  Sara K Quinney; Xin Zhang; Aroonrut Lucksiri; J Christopher Gorski; Lang Li; Stephen D Hall
Journal:  Drug Metab Dispos       Date:  2009-11-02       Impact factor: 3.922

6.  Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.

Authors:  Daniel Moj; Nina Hanke; Hannah Britz; Sebastian Frechen; Tobias Kanacher; Thomas Wendl; Walter Emil Haefeli; Thorsten Lehr
Journal:  AAPS J       Date:  2016-11-07       Impact factor: 4.009

7.  A Clinical Cassette Dosing Study for Evaluating the Contribution of Hepatic OATPs and CYP3A to Drug-Drug Interactions.

Authors:  Takashi Yoshikado; Kazuya Maeda; Sawako Furihata; Hanano Terashima; Takeshi Nakayama; Keiko Ishigame; Kazunobu Tsunemoto; Hiroyuki Kusuhara; Ken-Ichi Furihata; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2017-05-08       Impact factor: 4.200

Review 8.  Clinical pharmacokinetics of clarithromycin.

Authors:  K A Rodvold
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

9.  The effect of hydroxy metabolites of clarithromycin to the pharmacokinetic parameters, and determination of hydroxy metabolites ratio of clarithromycin.

Authors:  Durisehvar Unal; Aysen Fenercioglu; Latif Ozbay; Banu Ozkirim; Dilek Erol
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Oct-Dec       Impact factor: 2.441

10.  Computing with evidence Part II: An evidential approach to predicting metabolic drug-drug interactions.

Authors:  Richard Boyce; Carol Collins; John Horn; Ira Kalet
Journal:  J Biomed Inform       Date:  2009-06-16       Impact factor: 6.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.